Analysis of pre-treatment markers predictive of treatment benefit for the therapeutic cancer vaccine MVA-5T4 (TroVax).
about
Immunotherapeutic strategies for the treatment of renal cell carcinoma: where are we now?Therapeutic cancer vaccines and combination immunotherapies involving vaccinationA transient increase in eosinophils is associated with prolonged survival in men with metastatic castration-resistant prostate cancer who receive sipuleucel-T.Immunological response and overall survival in a subset of advanced renal cell carcinoma patients from a randomized phase 2/3 study of naptumomab estafenatox plus IFN-α versus IFN-α.Trial Watch: Therapeutic vaccines in metastatic renal cell carcinomaExtent of Systemic Spread Determines CD8+ T Cell Immunodominance for Laboratory Strains, Smallpox Vaccines, and Zoonotic Isolates of Vaccinia Virus.Specific immunotherapy in renal cancer: a systematic review.Identification of Pre- and Post-Treatment Markers, Clinical, and Laboratory Parameters Associated with Outcome in Renal Cancer Patients Treated with MVA-5T4.Designing effective vaccines for colorectal cancer.5T4 oncofoetal antigen: an attractive target for immune intervention in cancer.5T4 oncofoetal glycoprotein: an old target for a novel prostate cancer immunotherapy.Vaccination of castration-resistant prostate cancer patients with TroVax (MVA-5T4) in combination with docetaxel: a randomized phase II trial.Haptoglobin promoter polymorphism rs5472 as a prognostic biomarker for peptide vaccine efficacy in castration-resistant prostate cancer patients.
P2860
Q28301672-594C40D7-D72A-4461-B3D9-14F12776454EQ28397609-83C07B57-7682-4840-A4D8-262017405EFFQ34289239-AFB6BEA9-4792-41D6-BB0A-F014633AB2F7Q35552042-74C432E5-ACEA-4DF8-8799-6F07EABED434Q35799377-75424F2B-F601-442F-8322-4181F154B869Q35988486-4C31E590-1210-426B-93C5-CDCAC1528828Q37632182-B0216346-4A2E-4331-A782-C740C423204FQ38123176-4CEB05F5-12B2-450D-A603-2D5D954BA59AQ38260051-8F9CDCC9-D021-46DA-95B5-9A2CCED974FAQ38984929-3B4B9CD1-B01B-43B6-BF74-1D97795FC00DQ40188258-17EB34B5-9374-44A0-A6A6-F58801F8DC8BQ42282117-90F6C9CC-DDB4-4CB0-9C6E-72F19DEE189AQ52912696-7A77DCF9-B97E-4902-8538-7B4EA73B8473
P2860
Analysis of pre-treatment markers predictive of treatment benefit for the therapeutic cancer vaccine MVA-5T4 (TroVax).
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Analysis of pre-treatment mark ...... ncer vaccine MVA-5T4 (TroVax).
@en
Analysis of pre-treatment mark ...... apeutic cancer vaccine MVA-5T4
@nl
type
label
Analysis of pre-treatment mark ...... ncer vaccine MVA-5T4 (TroVax).
@en
Analysis of pre-treatment mark ...... apeutic cancer vaccine MVA-5T4
@nl
prefLabel
Analysis of pre-treatment mark ...... ncer vaccine MVA-5T4 (TroVax).
@en
Analysis of pre-treatment mark ...... apeutic cancer vaccine MVA-5T4
@nl
P2093
P2860
P1476
Analysis of pre-treatment mark ...... ancer vaccine MVA-5T4 (TroVax)
@en
P2093
Gemma Bolton
Jackie de Belin
Michelle Kelleher
Richard Harrop
Stuart Naylor
William H Shingler
P2860
P2888
P304
P356
10.1007/S00262-012-1302-9
P577
2012-06-13T00:00:00Z